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Abstract
Late breast implant seroma may be the presentation of a breast implant-associated anaplas-
tic large cell lymphoma (BI-ALCL), which claims for a prompt recognition. However, BI-ALCL
diagnosis on fine-needle aspiration (FNA) might be challenging for pathologists lacking
experience with peri-implant breast effusions. Sixty-seven late breast implant seromas col-
lected by FNA from 50 patients were evaluated by Papanicolaou smear stain and immunocy-
tochemistry on cell blocks. A diagnostic algorithm based on the cellular composition, cell
morphology and percentage of CD30+ cells was developed. Histological evaluation of the
corresponding peri-prosthetic capsules was also performed. Most of the effusions (91% of
the samples) were classified as reactive and 9% as BI-ALCL. In the BI-ALCL cases,
medium-to-large atypical cells expressing CD30 represented more than 70% of the cellular-
ity, whereas in in the reactive effusions CD30+ elements were extremely rare (<5%) and con-
sisted of non-atypical elements. The reactive effusions were categorized into three patterns:
i) acute infiltrate with prominent neutrophilic component (33% of the samples); ii) mixed infil-
trate characterized by a variable number of neutrophils, lymphocytes and macrophages
(30% of the samples); iii) chronic infiltrate composed predominantly of T lymphocytes or
macrophages with only sporadic granulocytes (37% of the samples). The inflammatory
cytological patterns were consistent with the histology of the corresponding capsules. Our
results indicate that cytological analysis of late breast implant effusions, supported by the
knowledge of the heterogeneous cytomorphological spectrum of late seromas, is a valuable
approach for the early recognition of BI-ALCL.
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Introduction
Late peri-implant seroma is a complication of breast prosthetic reconstruction and mammo-
plasty [1]. Among the causes of late seroma development, infection (even subclinical), implant
rupture, mechanical shearing, and breast implant-associated anaplastic large cell lymphoma
(BI-ALCL), have been reported. BI-ALCL is a provisional entity recently included within the
group of ALK-negative ALCLs [2]. It could manifest as a solid mass infiltrating the peri-pros-
thetic fibrotic capsule and soft tissues or, more frequently, as a late peri-implant seroma within
which tumor cells are confined [3], [4]. It has been suggested that the effusion and the mass
represent different stages of the same disease rather than two distinct clinicopathological vari-
ants and that they deserve different treatments [4], [5]. Since, the risk of lymph node involve-
ment and of systemic spread depends on the invasion of the capsule, implant removal and
total capsulectomy are indicated in non-invasive BI-ALCL, whereas systemic therapy is recom-
mended by some authors in infiltrating tumors [2]. Therefore, cytological examination of the
late peri-implant seroma emerges as a crucial procedure to clarify the nature of the effusion
and to promptly diagnose BI-ALCL.
BI-ALCL also can be diagnosed on capsulectomy specimens. Nevertheless, the identifica-
tion of localized BI-ALCL cases, in which scant tumor cell clusters adhere to the luminal
surface of the capsule, might be challenging, particularly when a wide sampling of the cap-
sule is not performed [6], [7], [8]. Flow cytometry (FC) may be a valuable tool for the diag-
nosis of BI-ALCL [9], [10]. However, in the routine diagnostic testing of late peri-implant
breast seromas flow cytometry is restricted to adequately equipped institutions and to
effusions with sufficient viable events. Moreover, as for the diagnosis of other large-cell lym-
phomas [11], flow cytometry studies on BI-ALCL highlighted several issues related to lym-
phomatous cells falling outside the typical lymphocyte region, to the marked loss of T cell
antigens, and to the variable expression of myeloid markers [9], [10]. These aspects, alto-
gether, may pose a diagnostic challenge and may give false-negative results when not inte-
grated with the morphologic evaluation of the cells and clinical data, particularly in cases
containing a low percentage of neoplastic cells. Hence, cytological evaluation of late peri-
capsular seromas emerges as the gold standard for a prompt BI-ALCL diagnosis. Neverthe-
less, the diagnosis of BI-ALCL based on the cytopathological examination of the late effu-
sion may be difficult for pathologists lacking experience with peri-implant breast effusions.
Detailed descriptions of the differential cytological features of BI-ALCL, as compared with
those characterizing non-neoplastic late effusions, have been only anecdotically reported
[7], [8]. In fact, over the past decade, implant-related seromas were not routinely submitted
to cytopathological evaluation. Yet, the knowledge of the cytological features characterizing
non-neoplastic late seromas is relevant to both the diagnosis and the treatment choice.
According to the type of the associated immune response, late seromas could be successfully
treated with more than one approach including antibiotics, percutaneous drainage, or cap-
sulectomy with implant replacement [1]. In particular, effusions rich in neutrophils are
most likely related to infections and deserve antibiotic therapy, while effusions with foamy
macrophages and multinucleated giant cells could suggest implant rupture and imply surgi-
cal treatment.
In this study we report the results of a comprehensive cytological and immunocytochemical
analysis of a large series of late seromas associated with breast implants, consecutively collected
over three years. The morphological spectrum of reactive and neoplastic seromas is detailed
providing a diagnostic algorithm for the cytological diagnosis of BI-ALCL and the subclassifi-
cation of the reactive effusions.
Diagnosis of breast implant late seromas
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Materials and methods
Case collection
Sixty-seven late onset peri-implant seromas (> 6 months from last breast surgery) from 50
patients were collected by ultrasound-guided fine-needle aspiration (US-FNA) and consecu-
tively analyzed at our Institution from 2013 to 2016. All the effusions were sampled by a 25
Gauge needle when more than 10ml of fluid were detected by US. Written informed consent
was obtained from patients upon sample collection. The study was performed in accordance
with the Declaration of Helsinki and approved by the Ethics Committee of Sant’Andrea Hospi-
tal/University “Sapienza” of Rome (EC n. 82 SA_2017).
Cytological preparation
Seroma samples were centrifuged at 2500 rpm for 10 minutes. After removal of the superna-
tant, Papanicolaou-stained smears were prepared from the buffy coat of the cell deposit. On
the smears a detailed evaluation of cytomorphological parameters including cellularity, size
of atypical cells, nuclear details (presence of nucleoli, nuclear shape), cytoplasmic details
(amount, presence of vacuoles), presence of mitoses, necrosis, apoptotic bodies, and the back-
ground appearances (serous, fibrinous, necrotic, hematic), was performed.
In addition to the preparation of conventional smears, fluids with an abundant cell deposit
were subjected to cell block preparation by mixing the remaining cell sediment with 200μl of
human plasma. Subsequently, 2 drops of thromboplastin (RecombiPlasTin 2G, Instrumenta-
tion Laboratory, Bredford, MA, USA) were added and mixed. The mixture was allowed to
stand for 2 minutes. The resultant clot was placed in a cassette, fixed with buffered formalin
and embedded in paraffin (FFPE). Cell blocks were sectioned at 2μm thickness and stained
with Haematoxylin and Eosin.
Microbiological culture
Twenty-one of the 61 reactive late seromas were sent for routine aerobic, anaerobic and fungal
cultures. Samples were incubated in brain-heart infusion broth (BHI) and in fluid thioglycol-
late medium (FTM) (BD Biosciences, California, USA). Samples were also streaked on Manni-
tol salt agar (MSA), Chocolate agar (CA), MacConkey agar (MCA), Sabouraud dextrose agar
(SAB), Columbia CNA Agar (CNA) and Columbia medium supplemented with 5% sheep
blood (COS) plates using sterile disposable inoculation loops and incubated at 37˚C overnight.
After 24 hours of incubation, the plates were observed for the presence of bacterial colonies. If
no growth was observed, the plates were incubated for an additional 24 hours at 37˚C. The
sample in which no bacterial growth was observed after 48 hours of incubation were recorded
as negative.
Surgical specimens
Capsulectomy specimens of the 5 BI-ALCL patients were obtained within a maximum of 16
days of the cytological diagnosis. In patient 2 the capsulectomy was not total; the residual cap-
sule was surgically removed 1 month later. To allow comparison between the cytologic and
histologic features, capsular specimens received within a maximum of 10 days from the
cytological diagnosis of reactive effusion were also evaluated. These consisted of 11 specimens
obtained from patients who underwent surgery for hematoma, capsular contracture, breast
implant rupture or relapsed seroma.
Diagnosis of breast implant late seromas
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Immunohistochemistry and assessment of staining
Immunohistochemistry on cell block and FFPE capsular specimens was performed using an
automated immunostainer (Dako, Glostrup, Denmark) with the following primary antibodies:
CD30 (clone Ber-H2), CD3 (clone F7.2.38), CD4 (clone 4B12), CD8 (clone C8/144B), CD68
(clone PG1), CD15 (clone Car-b), Granzyme B (clone GrB-7), IRF-4 (clone MUM1) (Dako),
CD25 (clone 4C9, Novocastra, Newcastle Upon Tyne, UK), PAX5 (clone SP34, Thermo
Scientific, Waltham, USA). Paraffin sections were pretreated using EnVision™ FLEX Target
Retrieval Solution (Dako) and incubated with an optimal dilution of the primary antibody.
The reaction was visualized with the EnVision Detection Kit (Dako) using 3–3’-diaminobenzi-
dine chromogenic substrate. Sections were counterstained with EnVision FLEX Hematoxylin
(Link) (Dako).
For every marker, positive cells were counted out of 10 non-overlapping randomly selected
high-power microscopic fields (HPFs, 40×10), and the mean number of positively stained cells
per HPF was recorded. The percentage of positive cells was calculated as the ratio between the
mean number of stained cells per HPF and the mean number of total cells per HPF.
Statistical methods
Student’s t-test for unpaired samples was used to compare the mean number of positive cells
for CD30, CD3, CD68, CD4, CD8, PAX5 and polymophonucleates (PMN) among the three
different types of reactive effusion (acute, chronic, mixed). P-values<0.05 were assumed as
statistically significant.
Clonality analysis of T-cell receptor gamma (TRG) gene
Molecular evaluation of the rearrangements of the gamma chain of the T-cell receptor (TCR)
was performed based on to the BIOMED-2 protocol using TRG rearrangements molecular
analysis kit (Master Diagnostica, Granada, Spain). The PCR amplification products were ana-
lyzed on a 3130 Genetic Analyzer (Applied Biosystems, Foster City, California) using the Gen-
eMapper software. Results were interpreted according to the guidelines for interpretation of
Ig/TCR clonality testing [12], [13] and in line with our previous experiences [14], [15]. The
assay was performed on the DNA extracted using the QIAamp DNAMini kit (Qiagen, Hilden,
Germany) from FFPE sections of the capsules of the 5 BI-ALCL cases and of the cell block of
one reactive seroma enriched in CD30+ elements.
Results
Clinical findings
Seroma specimens’ volume ranged from 20 to 600 mL and the color ranged from cloudy yel-
low to hemorrhagic (Fig 1A). Of the 67 late breast peri-mplant effusions collected from 50
patients, 65 were unilateral and 2 were bilateral. Thirty-eight out of 47 patients (81%) received
breast implant after breast carcinoma surgery, 9 patients (19%) received implants for cosmetic
reasons, while in 3 patients no clinical history was available. Forty-five out of 50 patients (90%)
had a reactive seroma and 5 patients (10%) were diagnosed with BI-ALCL. All the patients
were female, with a mean age at diagnosis of 51 years (range 35–72) for the BI-ALCL and of 53
years (range 23–75) for the reactive seroma patients. In the BI-ALCL group, the average time
to seroma presentation from implantation or last surgery was 70 months (range, 48–96),
whereas in the reactive group the average time to seroma development was 60 months (range,
6–137).
Diagnosis of breast implant late seromas
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Based on the pathological staging of BI-ALCL proposed by Clemens and Colleagues [4], the
5 patients with BI-ALCL had lymphoma confined to the fibrous capsule with no invasion of
the peri-capsular soft tissues and/or breast parenchyma. Involvement of controlateral axillary
lymph nodes was present in one case (patient 1) at the time of diagnosis. All the BI-ALCL
patients but one were treated with surgery alone (capsulectomy and implant removal); the
patient with lymph node involvement received surgery and adjuvant chemotherapy consisting
of 3 cycles of CHOEP (cyclophosphamide, hydroxydaunorubicin, vincristine, etoposide, pred-
nisone) [16] and achieved complete remission. The mean clinical follow-up time of BI-ALCL
patients was 36 months (range, 20–48). One of the five patients (patient 2) who had undergone
partial capsulectomy experienced local recurrence during follow-up; accordingly, surgical
removal of the residual fibrous capsule was performed. All the patients were disease-free at the
time of last follow-up in December 2016. The clinical and pathological features of the BI-
ALCL cases and of the reactive seromas are detailed in Table 1 and summarized in Table 2
respectively.
Cytological findings
Among the 67 effusions analyzed, 7 samples (10%) were hemorrhagic (3 cases), acellular (2
cases) or represented by scant foamy macrophages (2 cases), 54 samples (81%) were diagnosed
as benign inflammatory infiltrates, and 6 samples (9%) as BI-ALCL.
The smears of the neoplastic effusions showed large to medium-sized atypical cells (1.5-to-5
fold larger than a mature lymphocyte) with irregularly-shaped nuclei, prominent nucleoli and
abundant clear and often vacuolated cytoplasm. The morphology of the neoplastic cells
included hallmark cells with kidney-shaped nuclei, cells with multiple nuclei, binucleated
Reed-Stenberg-like cells and mononucleated cells with prominent single or multiple nucleoli
(Fig 2). Secondary features included the presence of a fibrinous background, apoptotic cells,
and scattered atypical mitotic figures (<1%). In one sample eosinophils were also detected in
the background. The cellularity varied from few large neoplastic cells admixed with small
mature lymphocytes and macrophages to numerous large-to-medium sized atypical elements
Fig 1. Late peri-implant breast seroma and total capsulectomy specimen of a patient with BI-ALCL. A. Ultrasound-guided fine-needle
aspiration of 100mL of left-sided breast peri-implant fluid collection. The color of the seroma ranged from cloudy yellow to blood-stained. B.
Grossly normal-appearing peri-prosthetic capsule with no evidence of solid or infiltrating masses.
https://doi.org/10.1371/journal.pone.0181097.g001
Diagnosis of breast implant late seromas
PLOS ONE | https://doi.org/10.1371/journal.pone.0181097 July 17, 2017 5 / 20
closely associated with small mature lymphocytes. In all the samples, atypical neoplastic cells
were CD30 positive and accounted for about 70% of the total cellularity. The smear of the
relapsed seroma, which occurred in one of the BI-ALCL patient, showed a mixture of lympho-
cytes and macrophages with scattered large atypical cells (Fig 2C) that upon CD30 immunos-
taining accounted for 10% of the total cellularity. Based on the presence of the CD30+ atypical
cells and of the previous BI-ALCL diagnosis the seroma was intepreted as disease relapse. The
immunophenotype of the BI-ALCL cases have been reported previously [17], [18] and is sum-
marized in Table 1. All the cases showed a T-cell defective phenotype (Fig 3) with complete
(case 1, 2, 3) or partial (case 4, 5) loss of CD3 expression. Most of the cases expressed CD4
except for case 3 that was CD8+ and for case 5 that expressed a CD4- CD8- double-negative
phenotype.
The cytological appearance of the reactive effusions was markedly heterogeneous among
patients. Based on the cellular composition of the inflammatory infiltrate and the percentage
of CD30+ elements, we developed a cytological diagnostic algorithm (Fig 4). The algorithm
allowed the distinction of reactive seromas from BI-ALCL, and the classification of the reactive
effusions into three main patterns: i) acute-type infiltrate with prominent polymorphonuclear
granulocyte infiltration, mainly neutrophilic (>50% of the total cellularity), associated with
some macrophages and scattered lymphocytes (18/54 samples, 33%); ii)mixed-type infiltrate
characterized by a variable number of neutrophils (ranging from 5% to 50% of the total cellu-
larity), admixed with lymphocytes and macrophages (16/54 samples, 30%); iii) chronic-type
infiltrate composed by lymphocytes, macrophages and sporadic polymorphonuclear granulo-
cytes, mainly eosinophils (<5% of the total cellularity) (20/54 samples, 37%) (Table 2 and Fig
4). In some of the chronic-type infiltrates (12 samples), the monocytic component, which
included foamy macrophages and multinucleated giant cells, outnumbered the lymphocytes
(macrophage-rich chronic-type infiltrates), while in other cases (8 samples) the lymphoid
Table 1. Clinical and pathological features of BI-ALCL samples.
Case 1 Case 2 Case 3 Case 4 Case 5
Age at diagnosis (years) 47 54 72 49 35
Time interval between
implant/last surgery and
late seroma (months)
72 60 72 96 48
Side of seroma Left Right Right Left Left
Reason for implant Reconstruction Reconstruction Cosmetic Reconstruction Cosmetic
Breast carcinoma Left-sided infiltrating ductal breast
carcinoma
Right-sided infiltrating
ductal breast
carcinoma
- Left-sided infiltrating
lobular breast carcinoma
-
Type of implant BIOCELL® textured silicone gel-
filled (Inamed); contralateral
breast augmentation with
BIOCELL® textured silicone gel-
filled (Inamed)
BIOCELL® textured
silicone gel-filled
(McGhan)
BIOCELL® textured silicone
gel-filled (Inamed) Replaced 8
years later with Polyurethane-
coated silicone (Polytech
Silimed)
BIOCELL® textured
silicone gel-filled
(Inamed)
Polyurethane-
coated silicone
(Polytech Silimed)
Treatment Implant removal, capsulectomy,
CHOEP
Implant removal,
capsulectomy
Implant removal, capsulectomy Implant removal,
capsulectomy
Implant removal,
capsulectomy
Follow-up (months) 48 42 41 27 20
Current status Disease-free Disease-free Disease-free Disease-free Disease-free
Immunophenotype CD30+, ALK-, CD8-, GrB+/-,
CD4+, CD3-, CD15+/-, IRF4+,
CD25+
CD30+, ALK-, CD8-,
GrB+/-, CD4+, CD3-,
CD15+/-, IRF4+,
CD25+
CD30+, ALK-, CD8+, GrB+,
CD4-, CD3-, CD15-, IRF4+/-,
CD25+
CD30+, ALK-, CD8-,
GrB-, CD4+, CD3+/-,
CD15+, PAX5-, IRF4+,
CD25+/-
CD30+, ALK-, CD8-
, GrB+/-, CD4-,
CD3+/-, CD15-
TRG gene rearrangement Polyclonal Monoclonal Monoclonal Monoclonal Monoclonal
Adapted from Di Napoli A. et al (Ref. 18)
https://doi.org/10.1371/journal.pone.0181097.t001
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elements predominated over the monocytes (lymphocyte-rich chronic-type infiltrates) (Fig 4).
Eight patients underwent multiple FNA along time: in 5 patients the pattern was unchanged,
whereas in 2 cases the pattern switched frommixed to chronic and in one case frommixed to
acute.
Matched cell blocks were available in 21 reactive effusions. Based on the composition of
the immune infiltrate cell block preparations were classified as follows: 6 acute infiltrates
Table 2. Clinical, microbiological and pathological features of reactive late seromas.
Clinical Features No. %
No of patients 45
Patients with recurrent seroma 8 18
Age at seroma presentation (years)
Mean 53
Range 23–75
Time interval between implant/last surgery and late seroma (months)
Mean 60
Range 6–137
Side
Left 25 56
Right 18 40
Bilateral 2 4
Reason for implant
Cosmetic 7 15
Reconstruction 35 78
n/a 3 7
Cytological Features No. %
N˚ of seromas 61
Type of seroma
Hemorrhagic/hypocellular/acellular 7 11
Cellular 54 89
Type of infiltrate
Acute 18 33
Mixed 16 30
Chronic 20 37
Microbiological culture No. %
N˚ of seromas 21
Type of infiltrate
Acute 9
non-sterile 4 44
sterile 5 56
Mixed 4
non-sterile 1 25
sterile 3 75
Chronic 6
non-sterile 0 0
sterile 6 100
Hemorragic 2
non-sterile 0 0
sterile 2 100
https://doi.org/10.1371/journal.pone.0181097.t002
Diagnosis of breast implant late seromas
PLOS ONE | https://doi.org/10.1371/journal.pone.0181097 July 17, 2017 7 / 20
(neutrophils>55% of the total cellularity), 6mixed infiltrates (neutrophils 8–54% of the total
cellularity), and 9 chronic infiltrates (neutrophils<8% of the total cellularity) (Table 3 and Fig
5). In all the 21 cell blocks, the infiltrate pattern proved to be concordant with that observed on
the corresponding smears. Immunocytochemical characterization showed a significant and
progressive enrichment in CD68+ macrophages and in CD3+ T-cells moving from acute to
mixed (CD68 p = 0.035; CD3 p = 0.0045) and from acute to chronic infiltrates (CD68 p =
0.0106; CD3 p = 0.0019) (Table 3). In the acute andmixed seromas, CD4+ lymphocytes out-
numbered the CD8+ cells, whereas in the chronic effusions almost equal proportions of CD4+
and CD8+ T lymphocytes were recorded. B-cells were scant or completely absent in all the
three patterns of reactive infiltrates, as confirmed by PAX5 immunostaining (Fig 5). Most
importantly, cell blocks allowed for the immunohistochemical detection of cells expressing
CD30 antigen, which, in the reactive effusion samples, were found with an average frequency
below 1% of the overall cellularity (mean 0.4%, range 0–5). Chronic effusions showed the
higher, although not statistically significant, percentage of CD30+ cells. (Table 3 and Fig 5).
Of note, the seroma of one of patient, a 32-years-old woman at the 8th week of gestation
with a monolateral effusion occurring 11 years after breast augmentation, was classified as a
chronic-type infiltrate and showed an unusually high fraction of CD30+ medium/large cells
accounting for 5% of the overall cellularity (Fig 6). Mitotic figures involving large CD30+ ele-
ments were also detected. The TRG rearrangement analysis performed on the DNA extracted
Fig 2. Aspirate smear of five cases of BI-ALCL. A. Case 1. B. Case 2. C. Relapse of case 2. D. Case 3. E. Case 4. F. Case 5. Smears
showed large to medium-size atypical cells with irregularly shaped nuclei, conspicuous nucleoli and abundant clear cytoplasm in a fibrinous
background. Morphologic features of BI-ALCL included hallmark cells with kidney-shaped nuclei (A arrows), binucleated Reed-Stenberg-
like cells (B and E), cells with multiple nuclei (D) and mononucleated cells with prominent single or multiple nucleoli (D, E, F) (Papanicolaou
smear, original magnification x400).
https://doi.org/10.1371/journal.pone.0181097.g002
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from the cell block, showed a predominant peak within a polyclonal background suggestive
for a T-cell restricted expansion. Although the effusion was not associated with acute signs of
inflammation, peripheral blood tests showed a mild neutrophilic leukocytosis (white blood cell
count = 11,000/μL, neutrophil percentage = 93%) and an elevated C-reactive protein
(CRP = 47mg/L). Based on these evidences a diagnosis of reactive seroma with excess of
CD30+ blasts was made and an antibiotic therapy (Ampicillin, 250 mg orally two times a day
for 10 days) was administered to the patient. In the 6 months following the diagnosis the
patient was well and did not manifest any sign of recurrent seroma.
Microbiological findings
Twenty-one out the 61 reactive late seromas were sent for culture. Based on cytological exami-
nation 9 effusions were classified as acute, 4 asmixed, 6 as chronic and 2 as hemorrhagic
(Table 2). Culture was positive in 1mixed-type seroma for both Pseudomonas aeruginosa and
Klebsiella oxytoca and in 4 acute-type effusions for Staphylococcus aureus (3/4 cases) and for
Serratia marcescens (1/4 cases). None of the 6 chronic-type seromas or of the 2 hemorragic effu-
sions showed pathogen growth.
Fig 3. Immunophenotypic characterization of BI-ALCL cell blocks. Representative cases are shown to underline the variability of CD3
expression in contrast to the consistent, intense and diffuse positivity for CD30 in BI-ALCL. In A CD3 was negative in almost all the tumor
cells. In B CD3 staining was heterogeneous with the lymphomatous cells being CD3-negative, CD3-weakly positive and CD3-strongly
positive. In C the majority of the neoplastic cells showed a faint CD3 expression (all original magnification x400).
https://doi.org/10.1371/journal.pone.0181097.g003
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Histological findings
The five patients with a cytological diagnosis of BI-ALCL underwent implant removal and cap-
sulectomy. Macroscopically, capsular specimens didn’t show the presence of solid masses (Fig
1B). Histological examination of the capsules confirmed the cytological diagnosis of BI-ALCL
(Fig 7). In all the cases clusters of medium to large size cells with irregularly shaped nuclei and
prominent nucleoli were found adherent to and within the luminal side of the fibrous capsule,
whereas small lymphocytes and histiocytes were dispersed throughout the remaining layers of
the capsule. Involvement of the contralateral axillary lymph node by CD30+ lymphomatous
cells clustered within the sinuses (metastatic-like pattern), was detected in case 1. In this case,
clonality analysis of the T-cell receptor gamma gene (TRG) performed on the DNA extracted
from both the peri-implant capsule and the involved lymph node (Fig 8A and 8B) failed to
identify a monoclonal peak. All the other BI-ALCL cases showed a monoclonal TRG rear-
rangement (Fig 8C, 8D, 8E and 8F).
In 11 of the patients diagnosed with reactive effusions (4 acute, 3mixed and 4 chronic) cap-
sulectomy performed for breast implant revision at the time of FNA allowed comparison of
the cytologic and histologic findings. In all the cases, the histology of the capsule was consistent
with the cytology of the corresponding effusion (Fig 9). In particular, those patients with acute
Fig 4. Algorithm for the cytological diagnosis of late peri-implant breast seromas based on morphology, cellular composition and
CD30 immunostaining.
https://doi.org/10.1371/journal.pone.0181097.g004
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pattern seromas showed a neutrophilic inflammatory infiltrate involving the peri-prosthetic
capsule and forming a granulation tissue (Fig 9C), whereas themixed and the chronic effusions
corresponded to a mononuclear chronic inflammation of the capsule, which in some cases was
associated with the occurrence of synovial metaplasia (Fig 9A). In cases with synovial metapla-
sia the degree of the associated lymphoid infiltration was milder than that of cases lacking the
metaplastic reaction (Fig 9B). A diffuse histiocytic reaction characterized by the presence of
foamy macrophages, pseudo-cystic spaces, giant-cells and foreign body materials was also
observed associated with chronic seromas (Fig 9E–9G). Of note, in one of these cases, aggre-
gates of macrophages on the luminal layer of a sclerotic and acellular capsule mimicked the
neoplastic cell clusters of BI-ALCL (Fig 9D). In this case, immunocytochemistry for CD68 and
CD30 proved diriment.
Discussion
BI-ALCL is a recently described lymphoma entity [2], which must be suspected in women
with late-onset breast peri-implant effusions [19], [20]. To date there are no data on the inci-
dence of BI-ALCL among patients with late seromas. The Food and Drug Administration
(FDA) has received 359 medical device reports (MDRs) of BI-ALCL, including nine deaths, in
the last six years [21]. Similarly, at May 2017 the registry created by the Italian Ministry of
Health in 2015 recorded 81 BI-ALCL cases in Europe [22]. In our experience, BI-ALCL cases
accounted for 9% of the unselected late peri-implant breast effusions, with most of them being
confined to the capsule. This result underlines the importance of a systematic cytological
screening of all late breast implant-related seromas.
As for other effusion-related lymphomas, cytological diagnosis of BI-ALCL might be chal-
lenging and may benefit from immunocytochemistry for CD30 [19], [23]. However, no guide-
lines for the morphological evaluation or tresholding of CD30+ cells in late seromas have been
so far provided. CD30 expression is not specific of lymphomatous cells [24], [25] being also
present on activated B and T lymphocytes, NK cells, monocytes and eosinophils [26], [27],
Table 3. Immunophenotype of reactive late-onset breast peri-implant effusions.
Type of infiltrate Cellularity CD30 (%) CD3 (%) CD4 (%)* CD8%)* Pax5 (%) CD68 (%)
Chronic (n.9)
Mean±SD 393±291 1±1,64 40±24 56±19 44±19 3±4 54±26
Max 800 5 63 84 70 13 98
Min 80 0 2 30 16 0 27
Mixed (n.6)
Mean±SD 483±475 0,15±0,30 31±19 65±11 35±10 1,74±1,79 45±22
Max 1200 1 53 77 50 5 75
Min 40 0 3 50 23 0 21
Acute (n.6)
Mean±SD 475±399 0,02±0.02 6±2 66±17 34±17 0,27±0,5 23±15
Max 1100 0,05 10 88 50 1 41
Min 75 0 3 49 12 0 5
p value
Acute vs Mixed 0,4885 0,157 0,0045 0,4529 0,4529 0,0416 0,0351
Acute vs Chronic 0,3244 0,1524 0,0019 0,1827 0,1842 0,0589 0,0106
Chronic vs Mixed 0,3267 0,2004 0,2323 0,1646 0,1662 0,2094 0,2522
* relative to the number of CD3+ cells
https://doi.org/10.1371/journal.pone.0181097.t003
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Fig 5. Cell block and immunohistochemistry of late onset breast peri-implant seromas. A. Acute-type reactive
effusion with numerous polymorphonucleates admixed with CD68+ macrophages and scattered CD3+ T-cells. B.
Chronic-type reactive effusion with predominance of foamy macrophages C. Chronic-type reactive effusion with
predominance of T cells. In all the reactive effusions CD30+ cells were very rare or absent. Scant PAX5+ B-cells were
detected in all types of seroma (H&E and immunohistochemistry original magnification x400).
https://doi.org/10.1371/journal.pone.0181097.g005
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[28]. Furthermore, CD30 expression can be induced on both T cells and B cells as a result of
viral infection [29] or upon activation under autoimmune and chronic inflammatory condi-
tions [30], [31], [32]. In almost all the reactive seromas we analyzed, CD30 identified small-to-
medium-size non-atypical elements accounting for less than 1% of the total cellularity. On the
contrary, in the neoplastic effusions CD30 stained the vast majority of the morphologically
atypical cells. Given this clear difference the distinction between reactive and lymphomatous
effusions might appear prosaic. Nevertheless, in the recurrent BI-ALCL seroma experienced
by one of our patient CD30+ atypical cells did not exceed 10% of the total cellularity whereas,
in the reactive seroma of the pregnant woman non-atypical proliferating CD30+ cells reached
5% of total cells. The morphology of the CD30+ elements together with the clinical data was
crucial for establishing both diagnoses. Interestingly, in the latter case the higher number of
CD30+ reactive cells might have related to the hormonal status of the patient, which might
have boosted the reactive inflammatory response inducing CD30 expression on non-
Fig 6. Morphological and molecular features of a CD30-rich reactive effusion. The seroma was composed mainly by CD3+ T cells
associated with scattered CD68+ macrophages and polymorphonucleates. Immunohistochemistry for CD30 stained a fraction of medium-
large proliferating cells equal to 5% of the total cellularity (H&E, original magnification x200; mitotic figures in the inserts x400). TRG (Vg 9/11
—Jg) clonality by Genescan fragment analysis showed a prominent peak (red arrows) within a polyclonal background in both the reference
size ranges given by the BIOMED2 protocol (black arrows).
https://doi.org/10.1371/journal.pone.0181097.g006
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Fig 7. Histology of the 5 cases of BI-ALCL. In all the cases CD30-positive neoplastic cells were confined within
the peri-prosthesis fibrous capsule. In case 3 and 5 tumor cells were smaller with a darker nuclei than case 1, 2, and
4. Small lymphocytes and histiocytes were sparse within the capsule. Arrows indicate polyurethane crystals in the
fibrinous/necrotic material adherent to the luminal side of the capsule. (original magnification x 100, insert x400).
https://doi.org/10.1371/journal.pone.0181097.g007
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neoplastic T cells. The observation of Piccinni and Colleagues that Progesterone promotes
both IL-4 production and membrane CD30 expression in established human Thl cell clones is
an intriguing link to this hypothesis [33]. Furthermore, in this case TRG clonality analysis
showed a prominent peak over a polyclonal background, consistent with an exaggerated reac-
tive expansion of a restricted T-cell population, likely selected by an unknown antigen [11],
[12]. Similarly, Kadin ME and collaborators have recently described a late seroma surrounding
a breast implant in which flow cytometry detected an expanded population of CD30+/CD3+ T
cells expressing TCRVβ13.2 in a polyclonal background [34]. Authors considered the seroma
as the manifestation of a CD30+ lymphoproliferative disorder. However, it is not clear to us,
which features favored this diagnosis, since authors reported the presence of “transformed
lymphocytes” in the effusion. Conversely, lack of TRGmonoclonality does not exclude malig-
nancy. In one of our BI-ALCL cases TRG analysis did not show a monoclonal rearrangement
in both the peri-implant capsule and the involved lymph node. We could not exclude the pres-
ence of a selective rearrangement of the beta chain (TRB), as reported in other ALCLs [35], or
alternatively, the possibility that it might correspond to a ‘molecular null-ALCL’, as found in
24% of ALK-positive and in 11% of ALK-negative ALCLs [36]. These findings highlight the
importance of collecting and integrating all clinical (e.g. signs of inflammation), laboratory
(e.g. microbiology, blood test), morphological (i.e. cellular composition and percentage of
Fig 8. TRG (Vγ If/10—Jγ) clonality by Genescan fragment analysis in BI-ALCL cases. An oligoclonal and a polyclonal pattern were
observed in the capsule (A) and in the involved axillary lymph node (B) of case 1 respectively. Monoclonal rearrangement identified by a
single high peak was found in case 2 (C), case 3 (D), and case 4 (E). Case 5 (F) showed a monoclonal biallelic rearrangement.
https://doi.org/10.1371/journal.pone.0181097.g008
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atypical CD30+ cells) and molecular data (i.e. T-cell receptor clonality testing by genescan frag-
ment analysis or flow cytometry) when diagnosing late seromas.
Most of the inflammatory effusions we analyzed were non-neoplastic in nature and cytolog-
ically nonspecific in terms of etiologic diagnosis. However, as with inflammatory responses in
other sites, the cellular composition and the relative abundance of the different immune cell
types may provide significant clues to the underlying cause. Neutrophilic inflammatory effu-
sions may indicate a bacterial infection. There are several reports in the literature dealing with
implant-related “early” and “late” infections [37], [38], [39], [40]. Late infections are generally
considered as resulting from bacteremia and secondary colonization of prosthesis with bacte-
ria entering the body at a distant site [40]. In textured implants Staphylococcus aureus and
Enterobacter spp were found to be the most frequent microorganisms involved [38], [39].
Additionally, the biofilm, a sessile community of microorganisms adherent on the surface of
the implants, has been related to antibiotic resistance in many subclinical infections and to the
risk of capsular contracture and BI-ALCL development [41]. Similarly to Chai SM et al, who
found that 3 out 6 reactive seromas were composed mainly of neutrophils associated with the
Fig 9. Histology of breast peri-implant fibrous capsules in patients with late-onset non-neoplastic seroma. A. Synovial metaplasia
of the luminal side of the capsule associated with mild lymphocitic infiltrate. B. Intense chronic inflammation with numerous lymphocytes and
plasmacells. C. Acute inflammation with neutrophils, edema and ectatic vessels. D. Sclerotic and acellular capsule with luminal aggregates
of CD68+ CD30- histiocytes. E. Diffuse histiocytic reaction with foamy macrophages and pseudo-cystic spaces containing gel-like refractile
and color-less material compatible with silicone (asterisk). F and G. Silicone and polyurethan crystals within phagocyte vacuoles of
multinucleated giant cells (original magnification H&E, CD30 and CD68 staining x200; F and G x400).
https://doi.org/10.1371/journal.pone.0181097.g009
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presence of granular proteinaceous debris suggestive of an acute inflammatory process [8], we
found an abundant neutrophilic infiltrate in 33% of the samples and bacterial growth in 44%
of the acute-type seromas cultured.
On the contrary, sterile serum and serosanguineous peri-prosthesis collections have been
associated with trauma causing breast implant rupture and bleeding from microfractures of
rigid capsules [42], with the use of oral anticoagulant therapy [43], and with prolonged inflam-
matory reactions leading to endothelial injury and capillary permeability [44], [45]. Although
no anamnestic data were available for most of our samples, we supposed that trauma, implant
microrupture and silicone gel tearing were the most likely causative events of the effusions in
which red blood cells and/or foamy macrophages and multinucleated giant cells were present.
In keeping with this hypothesis, we and others [8] observed foreign material, compatible with
silicone or polyurethan, within giant cells and macrophages in effusion smears and peri-
implant capsules.
We might speculate that lymphocyte-rich chronic seromas represent the response to a viral
infection or, alternatively, an exaggerated and persistent lymphoproliferation related to an
underlining immune disorder of the host, which might predispose to BI-ALCL development.
Molecular evidences of activating mutations of the JAK/STAT inflammatory pathway in
BI-ALCL samples [18], [46] and of a higher (although not statistically significant) percentage
of CD30+ cells detected in the chronic seromas support this hypothesis. Hence, among all ser-
oma associated with breast implant, the lymphocyte-rich ones might represent those who
deserve a more meticulous cytological evaluation (i.e. presence and percentage of atypical
CD30+ cells, pattern of T-cell receptor rearrangement) and a careful follow-up to allow the
identification of a possible malignant transformation of the CD30+ T-cell proliferation.
Lastly, themixed and the chronic- type effusions might represent the temporal evolution of
the acute form. Rheumatoid pleural effusion is an example of sterile exudative fluid in which
multiple thoracenteses have showed transition from neutrophil-predominant to lymphocyte-
predominant fluids [47]. In our experience, multiple FNA of late seromas showed that in the
same patient the pattern of infiltrate can change or remain stable over time. This phenomenon
could be intrinsically related to the causative agent or influenced by the therapy administered
(i.e. antibiotics).
Conclusions
Our study indicates that systematic cytological evaluation and CD30 immunostaining of all
late peri-implant breast seromas allow early recognition of BI-ALCL and provide information
about BI-ALCL incidence. The comprehensive cytological description of late seromas, inte-
grated in the diagnostic algorithm reported here, is intended as a compendium for the cytopa-
thologists in the prospect of an increasing number of breast effusions they will likely manage
in daily practice. The application of the diagnostic algorithm to larger series of seromas will
also offer the opportunity to validate or refine the proposed cut-off values in order to better
identify those cases warranting closer follow-up. Definitely, ad-hoc designed studies focusing
on the integration among anamnestic, imaging, laboratory, cytological and molecular data are
still needed to clarify the etiology of late seromas and the relationship, if any, with specific
patient’s characteristics, intrinsic implant feature, and the development of BI-ALCL.
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